Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 40 - 65 years~* Diagnosed metabolic syndrome~* Risk of cardiovascular death ≥ 5% (according to SCORE)~* Written informed consent~Exclusion Criteria:~* Women not in menopause or not using efficient contraception~* Known hypersensitivity to study drugs~* History of ischemic heart disease

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Fluvastatin: daily 80 mg, oral
- 2 (Type: EXPERIMENTAL): Valsartan
- 3 (Type: EXPERIMENTAL): Hydrochlorothiazide

Based on this trial design, predict the completion outcome and termination type (if applicable).